To determine the overall response rate for this regimen as determined by overall and disease-free survival. [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]

To evaluate the immune response of patients treated with this regimen based on the presence and characterization of tumor-infiltrating white blood cells [ Time Frame: 2 years ] [ Designated as safety issue: No ]

The prognosis of pancreatic cancer is extremely poor even with extensive surgery, and development of new treatment modalities is much-expected for cure of this disease. Dendritic cells (DCs) immunotherapy is expected favorable outcome when it is approached directly to the cancer tissue. To evaluate safety and immunological responses, we conducted a phase I/II study of intra-tumor DCs immunotherapy for pancreatic cancer patients.

Pregnancy (women of childbearing potential: Refusal or inability to use effective means of contraception)

Breast-feeder

Active or uncontrolled infection

Active or uncontrolled other malignancy

Steroids or immunosuppressing agent dependant status

Interstitial pneumonia

Decision of unsuitableness by principal investigator or physician-in-charge

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00795977